Dedicated specialist clinics can offer an extended surveillance programme for individuals with increased melanoma risk, such as those with CDKN2A GPVs (a major melanoma susceptibility gene) or with a personal history of multiple early onset melanomas (where a melanoma gene panel is negative). This evidence concerns the gene CDKN2A and melanoma.